Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Experimental group:Basic treatment combined Triazavirin
Control group:Basic treatment combined Triazavirin placebo
Sponsors
Health commission of Heilongjiang province
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) Adult aged >=18 years and agrees to sign the informed consent; (2) Laboratory-confirmed 2019-nCoV infection by real-time RT-PCR; (3) Chest imaging (CT) confirmed lung damage: multiple small plaques and stromal changes in the lungs, which were obvious in the outer lung, or multiple ground-glass shadows and infiltration shadows in both lungs, the changes may not be present in mild patients; (4) Hospitalized patients with fever (axillary temperature >=37.0 degree C) or respiratory symptoms; (5) The interval between symptom onset and randomization was within 12 days; (6) Did not participate in other clinical researches within 3 months; (7) Do not participate other antiviral studies within 28 days of follow-up.
Exclusion criteria
Exclusion criteria: (1) The PI considers that the patient is not suitable to participate the study or the patient may be unsafe if he participate the study; (2) Patients with serious liver disease, grade C according to child-pugh; (3) Patients with severe renal impairment (glomerular filtration rate <=30mL/min/1.73m2) or who have received continuous renal replacement therapy, hemodialysis or peritoneal dialysis; (4) Patients with severe anemia, Hgb < 60g/L. (5) Pregnant women or women with pregnancy test positive or breastfeeding women; (6) Patients with allergy history of Triazavirin or its components; (7) Confused to sign the informed consent; (8) Patients may be transferred to another hospital within 72h; (9) Received any experimental treatment for novel coronavirus infection within 30 days prior to screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to Clinical recovery; | — |
Secondary
| Measure | Time frame |
|---|---|
| Antifebrile time;Inflammatory absorption of chest CT;Intervals from positive to negative of Nucleic acid test;Mortality rate;conversion rate of severe patients; | — |
Countries
China
Contacts
Public ContactBaofeng Yang
Heilongjiang Province hospital
Outcome results
None listed